Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s): N.PFE

Healthcare

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Add To Watchlist

Recent & Breaking News (NYSE:PFE)

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire January 3, 2017

Opko Health's Phase 3 Data Sends Stock Plunging

Benzinga.com December 30, 2016

Bank of America, Facebook, Micron, Pfizer Inc. and Starbucks offer trade returns of over 23%

PR Newswire December 29, 2016

Expensive Breakups In 2016 Surpass GDPs Of Dozens Of Developing Nations

Benzinga.com December 28, 2016

Investors: Target a 21% return on Facebook, or get option-trade ideas on General Electric, Pfizer Inc., Walmart Stores Inc. and Weight Watchers or any stock you choose

PR Newswire December 23, 2016

Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca

Business Wire December 23, 2016

FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer

Business Wire December 21, 2016

Circle Pharma, Developer of Macrocyclic Peptide Therapeutics, Announces Series A Financing and Appoints Walter H. Moos, Ph.D., to Its Board

Business Wire December 21, 2016

7 Companies That Could Be Acquired In 2017

Benzinga.com December 20, 2016

Draper to Build Preclinical Microphysiological Systems with Pfizer to Help Predict Clinical Outcomes

Marketwired December 20, 2016

Jefferies' 2017 Global Pharma Outlook

Benzinga.com December 19, 2016

Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older

Business Wire December 19, 2016

FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX® (varenicline) Labeling

Business Wire December 16, 2016

Research Reports on Drug Makers Equities -- Pfizer, Merck, AbbVie, and Johnson & Johnson

PR Newswire December 16, 2016

Bank of America, Ford, General Electric, Pfizer Inc., and Wells Fargo & Co. and more offer option-trading opportunities that offer returns of more than 20%

PR Newswire December 15, 2016

Watch These 5 Huge Put Purchases In Thursday Trade

Benzinga.com December 15, 2016

CORRECTING and REPLACING Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)

Business Wire December 14, 2016

Sheridan Memorial Hospital First to Implement Interoperable Alarm Technology Between Cerner and Hospira

GlobeNewswire December 14, 2016

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer

Business Wire December 14, 2016

Ab Initio Announces Strategic Collaboration with Pfizer to Discover GPCR Activating Antibodies

Business Wire December 13, 2016